A Laboratory Confirms Good Results of the chikungunuña Vaccine
6 Articles
6 Articles
"94 percent of the 221 healthy adults who participated in the trial maintained neutralising antibody levels well above the seropositive threshold five years after a single injection of the vaccine," according to the pharmaceutical group. Ixchiq vaccine is one of the few available against chikungunuña, a viral disease transmitted among humans by the bite of a mosquito that causes fevers and joint pains.
The Valneva laboratory confirmed that 94% of participants in a clinical trial maintained antibodies against chikungunuña for five years.
The Ixchiq vaccine against chikungunya is effective up to five years after the application of a single dose, announced on Tuesday (10) the Franco-Austrian laboratory Valneva. Read more (11/10/2026
The Ixchiq vaccine against chikunguna is effective up to five years after the application of a single dose, announced on Tuesday the French-Austrian laboratory Valneva, which manufactures it." 94% of the 221 healthy adults who participated in the trial maintained neutralizing antibody levels well above the HIV threshold five years after a single injection of the vaccine," according to the pharmaceutical group.The Ixchiq vaccine is one of the few…
Ixchiq vaccine from the Valneva laboratory shows efficacy for up to five years, despite suspensions and re-evaluations in countries such as USA and France
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
